Dr. Bernard Chiasson, Ph.D.
Chief Scientific Officer
Dr. Chiasson has 25 years of experience in pharmaceuticals and biotechnology. He has held positions of increasing responsibility in Research and Development including drug discovery, medical and clinical affairs, business development and licensing, regulatory affairs and executive management. In his role at Nuvo he is responsible for oversight of the scientific areas, including: regulatory, safety, clinical, medical and quality.
During his time in industry, he has worked on several small molecules, biologics and biotechnology products at various stages of product development including the final registration phase with Health Canada and the US FDA. He has industry experience in a variety of therapeutic areas and has developed strategies and franchise management approaches for pre-market and marketed products in various categories including Inflammation, Dermatology and Neurology to mention a few. He obtained his industry training with Novartis, Draxis Health, Bayer Biologics, Amgen, Optum and Tribute Pharmaceuticals Inc. Most recently, he was Chief Scientific Officer at Tribute Pharmaceuticals Inc. and part of the executive team that grew the company to a final merger that saw a rise of approximately ten times the market capitalization during his tenure. Prior to Tribute, Dr. Chiasson was VP of US Strategic Regulatory Affairs and Global Medical Services at Optum where he was responsible for a team of scientists and physicians supporting client drug development, safety and regulatory strategies and operations.
Bernie is a trained neuroscientist and pharmacologist and received a BSc (hons), MSc. (Physiology and Biophysics) and PhD (Neuroscience and Pharmacology) from Dalhousie University and conducted his Post-Doctoral studies at the University of Toronto.